openPR Logo
Press release

Exocrine Pancreatic Insufficiency Treatment Market 2034: FDA Approvals, Clinical Trials, Pipeline, Prevalence and Companies by DelveInsight | First Wave BioPharma, Abbott, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Lab

07-11-2024 07:05 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Exocrine Pancreatic Insufficiency Treatment Market

Exocrine Pancreatic Insufficiency Treatment Market

(Albany, USA) DelveInsight's "Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Exocrine Pancreatic Insufficiency, historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Exocrine Pancreatic Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Exocrine Pancreatic Insufficiency Market Forecast
https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Exocrine Pancreatic Insufficiency Market Report:
• The Exocrine Pancreatic Insufficiency market size was valued approximately USD 2,500 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2022, Alcresta Therapeutics, Inc., a prominent commercial-stage company dedicated to the development and commercialization of innovative enzyme-based products, revealed a set of significant milestones for RELiZORB.
• In February 2022, Researchers from the University of Miami conducted a survey with patients regarding their utilization of pancreatic enzyme replacement therapy (PERT) and identified a deficiency in education about this treatment.
• Within the 7MM, the United States recorded the highest prevalence of EPI, with a total of 176,112 cases in 2021, and projections indicate a further increase during the forecast period (2022-2032).
• According to Delveinsight's analysis in Germany, there were a combined total of 10,088, 24,665, 5,792, and 4,704 cases of EPI resulting from Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis, and Unresectable Pancreatic Cancer, respectively, in the year 2021.
• Key Exocrine Pancreatic Insufficiency Companies: First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories, First Wave BioPharma, Inc., Anthera Pharmaceuticals, and others
• Key Exocrine Pancreatic Insufficiency Therapies: FWEPI/MS1819, Pancreatin, VIOKASE 16, Pancrelipase Delayed Release, SA-001, EUR-1008, adrulipase, Liprotamase, and others
• The Exocrine Pancreatic Insufficiency epidemiology based on gender analyzed that No gender difference was observed in the case of EPI
• The Exocrine Pancreatic Insufficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Exocrine Pancreatic Insufficiency pipeline products will significantly revolutionize the Exocrine Pancreatic Insufficiency market dynamics.

Exocrine Pancreatic Insufficiency Overview
Exocrine pancreatic insufficiency (EPI) is a condition where the pancreas fails to produce or release adequate amounts of digestive enzymes, leading to improper digestion and nutrient absorption. This can result from chronic pancreatitis, cystic fibrosis, pancreatic surgery, or other conditions affecting the pancreas.
The primary symptoms of Exocrine Pancreatic Insufficiency include weight loss, diarrhea, steatorrhea (fatty stools that are bulky and foul-smelling), abdominal pain, and bloating. These symptoms are due to the malabsorption of fats, proteins, and carbohydrates, leading to nutritional deficiencies and overall poor health.
Diagnosis of Exocrine Pancreatic Insufficiency typically involves a combination of clinical evaluation, stool tests to measure fat content, and blood tests to check for nutritional deficiencies. Imaging studies, such as CT scans or MRI, may also be used to assess the structure of the pancreas.
Exocrine Pancreatic Insufficiency Treatment focuses on replacing the missing pancreatic enzymes with pancreatic enzyme replacement therapy (PERT), which is taken with meals to aid digestion. Additionally, dietary modifications, such as a low-fat diet and supplementation of fat-soluble vitamins (A, D, E, K), are often recommended. Managing the underlying cause of Exocrine Pancreatic Insufficiency, if possible, is also crucial.
Early diagnosis and proper management of Exocrine Pancreatic Insufficiency can significantly improve symptoms, enhance nutrient absorption, and improve the overall quality of life for affected individuals.

Get a Free sample for the Exocrine Pancreatic Insufficiency Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Exocrine Pancreatic Insufficiency Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Exocrine Pancreatic Insufficiency Epidemiology Segmentation:
The Exocrine Pancreatic Insufficiency market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Exocrine Pancreatic Insufficiency
• Prevalent Cases of Exocrine Pancreatic Insufficiency by severity
• Gender-specific Prevalence of Exocrine Pancreatic Insufficiency
• Diagnosed Cases of Episodic and Chronic Exocrine Pancreatic Insufficiency

Download the report to understand which factors are driving Exocrine Pancreatic Insufficiency epidemiology trends @ Exocrine Pancreatic Insufficiency Epidemiology Forecast
https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Exocrine Pancreatic Insufficiency Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Exocrine Pancreatic Insufficiency market or expected to get launched during the study period. The analysis covers Exocrine Pancreatic Insufficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Exocrine Pancreatic Insufficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Exocrine Pancreatic Insufficiency Therapies and Key Companies
• FWEPI/MS1819: First Wave BioPharma
• Pancreatin: Abbott Products
• VIOKASE 16: AAIPharma
• Pancrelipase Delayed Release: Solvay Pharmaceuticals
• SA-001: Abbott
• EUR-1008: Forest Laboratories
• adrulipase: First Wave BioPharma, Inc.
• Liprotamase: Anthera Pharmaceuticals

Discover more about therapies set to grab major Exocrine Pancreatic Insufficiency market share @ Exocrine Pancreatic Insufficiency Treatment Landscape
https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Exocrine Pancreatic Insufficiency Market Drivers
• Delivery system strategies
• Advanced therapeutics for the treatment of exocrine pancreatic insufficiency
• Increasing global occurrence of exocrine pancreatic insufficiency
• Research and developmental strategies

Exocrine Pancreatic Insufficiency Market Barriers
• Lack of technological reach and awareness
• Lack of confidence in diagnosis and management
• Treatment failure to stimulate and follow society's goals and requirements

Scope of the Exocrine Pancreatic Insufficiency Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Exocrine Pancreatic Insufficiency Companies: First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories, First Wave BioPharma, Inc., Anthera Pharmaceuticals, and others
• Key Exocrine Pancreatic Insufficiency Therapies: FWEPI/MS1819, Pancreatin, VIOKASE 16, Pancrelipase Delayed Release, SA-001, EUR-1008, adrulipase, Liprotamase, and others
• Exocrine Pancreatic Insufficiency Therapeutic Assessment: Exocrine Pancreatic Insufficiency current marketed and Exocrine Pancreatic Insufficiency emerging therapies
• Exocrine Pancreatic Insufficiency Market Dynamics: Exocrine Pancreatic Insufficiency market drivers and Exocrine Pancreatic Insufficiency market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Exocrine Pancreatic Insufficiency Unmet Needs, KOL's views, Analyst's views, Exocrine Pancreatic Insufficiency Market Access and Reimbursement

To know more about Exocrine Pancreatic Insufficiency companies working in the treatment market, visit @ Exocrine Pancreatic Insufficiency Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Exocrine Pancreatic Insufficiency Market Report Introduction
2. Executive Summary for Exocrine Pancreatic Insufficiency
3. SWOT analysis of Exocrine Pancreatic Insufficiency
4. Exocrine Pancreatic Insufficiency Patient Share (%) Overview at a Glance
5. Exocrine Pancreatic Insufficiency Market Overview at a Glance
6. Exocrine Pancreatic Insufficiency Disease Background and Overview
7. Exocrine Pancreatic Insufficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Exocrine Pancreatic Insufficiency
9. Exocrine Pancreatic Insufficiency Current Treatment and Medical Practices
10. Exocrine Pancreatic Insufficiency Unmet Needs
11. Exocrine Pancreatic Insufficiency Emerging Therapies
12. Exocrine Pancreatic Insufficiency Market Outlook
13. Country-Wise Exocrine Pancreatic Insufficiency Market Analysis (2020-2034)
14. Exocrine Pancreatic Insufficiency Market Access and Reimbursement of Therapies
15. Exocrine Pancreatic Insufficiency Market Drivers
16. Exocrine Pancreatic Insufficiency Market Barriers
17. Exocrine Pancreatic Insufficiency Appendix
18. Exocrine Pancreatic Insufficiency Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/carcinoid-tumor-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Central Serous Chorioretinopathy Market: https://www.delveinsight.com/report-store/central-serous-chorioretinopathy-market
• Hemophilia B Market: https://www.delveinsight.com/report-store/hemophilia-b-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exocrine Pancreatic Insufficiency Treatment Market 2034: FDA Approvals, Clinical Trials, Pipeline, Prevalence and Companies by DelveInsight | First Wave BioPharma, Abbott, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Lab here

News-ID: 3577387 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Exocrine

Increasing Prevalence Of Chronic Diseases Boosts Growth Prospects For The Exocri …
The Exocrine Pancreatic Insufficiency Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Exocrine Pancreatic Insufficiency Market? In recent times, the market size for exocrine pancreatic insufficiency has experienced robust growth. Expected to rise from $2.59 billion in 2024 to
Prominent Exocrine Pancreatic Insufficiency Market Trend for 2025: Exocrine Panc …
What Are the Projected Growth and Market Size Trends for the Exocrine Pancreatic Insufficiency Market? The exocrine pancreatic insufficiency market has seen strong growth in recent years. It is projected to increase from $2.59 billion in 2024 to $2.76 billion in 2025, at a compound annual growth rate (CAGR) of 6.6%. The growth is driven by factors such as increased awareness and diagnosis, the rising prevalence of digestive disorders, an aging
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Exocrine Pancreatic Insufficiency Market - Positive long-term growth outlook 202 …
Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of exocrine pancreatic enzymes, resulting in the inability to digest food properly, a condition called maldigestion. These enzymes consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. EPI results from various diseases such as cystic fibrosis, chronic pancreatitis, pancreatic cancer, cytomegalovirus infection, and HIV/AIDS. The symptoms of EPI are maldigestion or malabsorption and specifically
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,
Exocrine Pancreatic Insufficiency Market Research and Forecast Report 2023
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market - (Therapeutic - Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,